,21 Although beneficial to treat MASH,22–24 these whole-body FXR agonists result in off-target effects such as an imbalance in cholesterol homeostasis by elevating LDL, pruritus, abdominal discomfort, and fatigue.25 Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.